JAK inhibition and the holy grail for pain control in early RA

RMD Open. 2022 Jan;8(1):e002068. doi: 10.1136/rmdopen-2021-002068.
No abstract available

Keywords: arthritis; patient reported outcome measures; rheumatoid; therapeutics.

Publication types

  • Editorial

MeSH terms

  • Antirheumatic Agents* / therapeutic use
  • Humans
  • Janus Kinase Inhibitors* / pharmacology
  • Janus Kinase Inhibitors* / therapeutic use
  • Pain / drug therapy
  • Pain / etiology
  • Pain Management

Substances

  • Antirheumatic Agents
  • Janus Kinase Inhibitors